Domača stranBNTX • NASDAQ
add
BioNTech
110,64 $
Po zaprtju:(1,24 %)+1,37
112,01 $
Konec trgovanja: 8. nov., 19:39:11 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
107,88 $
Dnevni razpon
110,01 $ - 115,32 $
Letni razpon
76,53 $ - 131,49 $
Tržna kapitalizacija
26,31 mrd. USD
Povprečni obseg
688,05 tis.
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,24 mrd. | 39,04 % |
Stroški poslovanja | 1,04 mrd. | 53,43 % |
Čisti dohodek | 198,10 mio. | 23,35 % |
Čista dobičkovnost prihodkov | 15,91 | −11,32 % |
Earnings per share | 0,81 | 20,90 % |
EBITDA | 65,30 mio. | −30,31 % |
Efektivna davčna stopnja | −24,83 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 16,71 mrd. | 6,10 % |
Skupna sredstva | 22,40 mrd. | 0,87 % |
Skupne obveznosti | 3,29 mrd. | 40,43 % |
Celoten lastniški kapital | 19,11 mrd. | — |
Shares outstanding | 239,74 mio. | — |
Razmerje P/B | 1,35 | — |
Donosnost sredstev | 0,23 % | — |
Donosnost kapitala | 0,27 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 198,10 mio. | 23,35 % |
Denar iz dejavnosti | −638,90 mio. | −178,76 % |
Denar iz naložb | −142,10 mio. | 88,47 % |
Denar iz financiranja | −7,90 mio. | 97,46 % |
Neto sprememba denarnih sredstev | −752,10 mio. | −12,12 % |
Prost denarni tok | −684,45 mio. | −217,91 % |
Vizitka
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.
In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the United Kingdom. It was the first mRNA vaccine ever authorized. Wikipedia
Generalni direktor
Datum ustanovitve
2008
Spletno mesto
Zaposleni
6.133
